Zevra Therapeutics (ZVRA) Cost of Revenue (2019 - 2026)

Zevra Therapeutics has reported Cost of Revenue for 7 years, with the latest figure at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 41.04% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $17.0 million (up 98.37% YoY), and the FY2025 full-year result was $16.5 million, up 122.22% from the prior year.
• Cost of Revenue for Q1 2026 stood at $1.9 million, up from $1.5 million in the prior quarter.
• The five-year high for Cost of Revenue was $12.4 million in Q2 2025, with the low at $8000.0 in Q1 2022.
• Historically, Cost of Revenue has averaged $1.7 million across 5 years, with a median of $1.2 million in 2023.
• Annual changes were most pronounced in 2022 — Cost of Revenue tumbled 98.0% — and 2023, when it jumped 5477.27%.
• Zevra Therapeutics' Cost of Revenue stood at $22000.0 in 2022, then jumped by 5477.27% to $1.2 million in 2023, then climbed by 11.33% to $1.4 million in 2024, then climbed by 11.27% to $1.5 million in 2025, then climbed by 24.8% to $1.9 million in 2026.
• The last three Cost of Revenue figures came in at $1.9 million (Q1 2026), $1.5 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.